ICOSLG and systemic lupus erythematosus: Prezalumab, a fully human IgG2a antibody targeting ICOSL, formerly known as AMG-557, has shown safety and potential efficacy in clinical trials of patients with Sjogren’s syndrome and SLE (108, 122, 123).